Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165836 | 0.88 | CA1 (0.46) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16535444 | 0.84 | HPGD (0.45) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16015104 | 0.84 | CA1 (0.44) | CA1CA2CA9CA12CA3 | |
| SCHEMBL529423 | 0.82 | CYP17A1 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21191026 | 0.81 | CA1 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL529204 | 0.81 | KIF11 (0.45) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14880907 | 0.79 | CA12 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL20634263 | 0.78 | CA1 (0.37) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21190941 | 0.78 | BRD4 (0.46) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21191095 | 0.78 | CA1 (0.37) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2598481-B1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8916553-B2 | Sulfonamide compounds useful as CYP17 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-23 | — | — | US | disclosed |
| US-8859611-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2512247-B1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-29 | — | — | US | disclosed |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586624-B2 | Thiophene inhibitors of S-nitrosoglutathione reductase | N30 PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2598481-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2512247-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 Pharmaceuticals, LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | N30 PHARMACEUTICALS, LLC (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015723-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2011075478-A1 | NOVEL THIOPHENE INHIBITORS OF S-NITROSOGLUTATHIONE REDUCTASE | N30 PHARMACEUTICALS, LLC (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7906530-B2 | 1,7-naphthyridine derivatives as p38 MAP kinase inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-03-15 | — | — | US | disclosed |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-09-09 | — | — | US | disclosed |
| EP-2049537-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017461-A1 | 1, 7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148453-A1 | SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS | SULT1A1, SULT2A1, SULT1E1 | CA1 1477/4885CA2 1445/4885CA9 918/4885 |
| US-20140057957-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | CA1 4614/4885CA2 3307/4885CA9 3893/4885 |
| US-20100227881-A1 | 1,7-NAPHTHYRIDINE DERIVATIVES AS P38 MAP KINASE INHIBITORS | MAPK1, MAPK7, MAPKAPK2 | CA1 4829/4885CA2 4678/4885CA9 4835/4885 |
| US-20120245210-A1 | Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase | GSR, GRHPR, POR | CA1 4614/4885CA2 3307/4885CA9 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.